The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer: A real-world database study.
 
Yusuke Kawanaka
No Relationships to Disclose
 
Chiaki Inagaki
Stock and Other Ownership Interests - Eisai
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD; Taiho Pharmaceutical
Research Funding - Astellas Pharma; Epochal Precision Anti-Cancer Therapeutics; Ono Pharmaceutical
Travel, Accommodations, Expenses - Takeda
 
Takayuki Takahama
Speakers' Bureau - AstraZeneca Japan; Chugai Pharmaceutical Co Ltd.; MSD K.K; Roche Diagnostics Solutions
Research Funding - Pfizer; Takeda
 
Satomi Watanabe
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kirin Pharmaceuticals; MSD K.K
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
 
Seiichiro Mitani
Honoraria - Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - Lilly; Taiho Pharmaceutical
 
JUNKO TANIZAKI
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Daiichi sankyo Co., Ltd.; EMD Serono/Merck; Janssen; Lilly Japan; MSD; Nihon Medi-Physics; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED
Speakers' Bureau - Abbvie; AstraZeneca Japan
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takeshi Yoshida
Honoraria - Daiichi Sankyo; Pfizer
 
Tsutomu Iwasa
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; GlaxoSmithKline; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kazuko Sakai
Honoraria - Nippon Kayaku; Qiagen, Inc.; Takeda; YODOSHA
 
Kimio Yonesaka
No Relationships to Disclose
 
Kazuto Nishio
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; DAIICHI SANKYO; Guardant Health; Invitae Japan; Janssen; Lilly Japan; Maruho; MSD K.K.; Nichirei; Novartis; Ono Pharmaceutical; Otsuka; SymBio Pharmaceuticals
Research Funding - Hitachi Chemical; Lilly Japan; Nichirei; Nippon Boehringer Ingelheim; Osaka Minami Hospital; Otsuka; SYSMEX; West Japan Oncology Group
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb Company; Chugai Pharma; Daiichi Sankyo Co., Ltd.; Global Health Consulting Japan Co., Ltd.; Hisamitsu Pharmaceutical; Incyte; Janssen; Lilly Japan; M3; Medical Mobile Communications; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; The Yomiuri Shimbun; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - A2 Healyhcare Corp. (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Cancer Research Organization (Inst); Kobayashi Pharmaceutical (Inst); Labcorp Drug Development (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thoracic Oncology Research Group (Inst)
 
Hidetoshi Hayashi
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Janssen; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Kirin Co., Ltd (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Medpace Japan KK (Inst); Merck (Inst); MSD K.K. (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA Health Sciences Inc. (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex